Aspirin for primary prevention of atherosclerotic cardiovascular events

Aldo L Schenone1, A Michael Lincoff2

  • 1Non-Invasive Cardiovascular Imaging Department, Brigham and Women's Hospital, Boston, MA.

Insights

Aspirin use for primary prevention of cardiovascular events is limited in intermediate-risk patients, diabetics, and the elderly, according to recent guidelines. Its effectiveness in higher-risk individuals requires further investigation.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Background:

  • Cardiovascular disease remains a leading cause of mortality worldwide.
  • Primary prevention strategies aim to reduce the incidence of first-time cardiovascular events.
  • Aspirin has been widely studied for its potential role in cardiovascular prevention.

Purpose of the Study:

  • To synthesize recent trial data on aspirin for primary cardiovascular prevention.
  • To evaluate the current evidence for aspirin's efficacy across different patient populations.
  • To inform clinical guidelines regarding aspirin's role in primary prevention.

Main Methods:

  • Systematic review of recent clinical trials.
  • Meta-analysis of cardiovascular event rates.
  • Inclusion of data from patients at intermediate risk, with diabetes, and the elderly.

Main Results:

  • Recent trials have informed current professional guidelines on aspirin use.
  • The role of aspirin in primary prevention is generally limited for the evaluated groups.
  • Evidence for aspirin's benefit in high-risk populations is currently insufficient.

Conclusions:

  • Current evidence supports a limited role for aspirin in primary cardiovascular prevention for most tested groups.
  • Further research is needed to determine aspirin's efficacy in individuals at higher cardiovascular risk.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
263
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
955
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
176
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
530
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
174
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.9K